nach oben

European Journal of Epidemiology

Erschienen in:

01.03.2014 | CARDIOVASCULAR DISEASE

A cohort study examination of established and emerging risk factors for atrial fibrillation: the Busselton Health Study

verfasst von: Matthew Knuiman, Tom Briffa, Mark Divitini, Derek Chew, John Eikelboom, Brendan McQuillan, Joseph Hung

Erschienen in: European Journal of Epidemiology | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Atrial fibrillation (AF) is the most common chronic arrhythmia in adults and its prevalence is increasing. Due to its serious cardiovascular complications there is a strong need to understand predisposing risk factors to develop effective prevention strategies. There are a few established risk factors but a number of further risk factors have been suggested including obesity, metabolic syndrome, sleep-disordered breathing, and inflammation. The aim of this study was to investigate established and emerging risk factors for AF in a cohort study of 4,267 adults in Busselton, Western Australia, without a history of AF at baseline in 1994/95 who were followed for 15 years for incident AF events. Baseline measurement included questionnaire, clinical assessment and blood sample. A total of 343 (8 %) experienced AF during follow-up. Cox regression analysis confirmed advancing age, male sex, taller height, being on hypertension treatment and higher body mass index (BMI) as the major common risk factors (all p < 0.001). However, further modelling showed the effect of being on hypertension treatment may be stronger in women (p = 0.001) and the effect of BMI stronger in men (p = 0.004). After adjustment for these factors, no other factors were strongly related (p < 0.001) although short PR interval, history of valvular heart disease, stroke, chronic obstructive pulmonary disease, lung function and adiponectin level were marginally related (p < 0.05). This cohort study of predictors for incident AF has confirmed the major established risk factors. However, recently suggested potential novel risk factors for AF (inflammation, sleep-disordered breathing, glucose/metabolic disorders) were not confirmed in this study.

Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82(7):2N–9N.PubMedCrossRef

Greenlee RT, Vidaillet H. Recent progress in the epidemiology of atrial fibrillation. Curr Opin Cardiol. 2005;20(1):7–14.PubMed

Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10):946–52.PubMedCrossRef

Chugh SS, Blackshear JL, Shen W-K, Hammill SC, Gersh BJ. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol. 2001;37(2):371–8.PubMedCrossRef

Stewart S, Hart CL, Hole DJ, McMurray JJV. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley Study. Am J Med. 2002;113:359–64.PubMedCrossRef

Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370–5. doi:10.1001/jama.285.18.2370.PubMedCrossRef

Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119–25. doi:10.1161/circulationaha.105.595140.PubMedCrossRef

Benjamin EJ, Chen P-S, Bild DE, Mascette AM, Albert CM, Alonso A, et al. Prevention of atrial fibrillation: report from a National Heart, Lung, and Blood Institute workshop. Circulation. 2009;119(4):606–18. doi:10.1161/circulationaha.108.825380.PubMedCentralPubMedCrossRef

Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997;96(7):2455–61.PubMedCrossRef

10.

Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. JAMA. 1994;271(11):840–4. doi:10.1001/jama.1994.03510350050036.PubMedCrossRef

11.

Schoonderwoerd BA, Smit MD, Pen L, Van Gelder IC. New risk factors for atrial fibrillation: causes of ‘not-so-lone’ atrial fibrillation. Europace. 2008;10(6):668–73. doi:10.1093/europace/eun124.PubMedCrossRef

12.

Wang TJ, Parise H, Levy D, D’Agostino RB, Wolf PA, Vasan RS, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA, J Am Med Assoc. 2004;292(20):2471–7. doi:10.1001/jama.292.20.2471.CrossRef

13.

Frost L, Hune LJ, Vestergaard P. Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish diet, cancer, and health study. Am J Med. 2005;118(5):489.PubMedCrossRef

14.

Dublin S, French B, Glazer NL, Wiggins KL, Lumley T, Psaty BM, et al. Risk of new-onset atrial fibrillation in relation to body mass index. Arch Intern Med. 2006;166(21):2322–8. doi:10.1001/archinte.166.21.2322.PubMedCrossRef

15.

Watanabe H, Tanabe N, Watanabe T, Darbar D, Roden DM, Sasaki S, et al. Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation. 2008;117(10):1255–60. doi:10.1161/circulationaha.107.744466.PubMedCentralPubMedCrossRef

16.

Marott SCW, Nordestgaard BG, Zacho J, Friberg J, Jensen GB, Tybjaerg-Hansen A, et al. Does elevated C-reactive protein increase atrial fibrillation risk? A mendelian randomization of 47,000 individuals from the general population. J Am Coll Cardiol. 2010;56(10):789–95. doi:10.1016/j.jacc.2010.02.066.PubMedCrossRef

17.

Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, D’Agostino RB Sr, et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. The Lancet. 2009;373(9665):739.CrossRef

18.

Chamberlain AM, Agarwal SK, Folsom AR, Soliman EZ, Chambless LE, Crow R, et al. A clinical risk score for atrial fibrillation in a biracial prospective cohort (from the Atherosclerosis Risk In Communities [ARIC] Study). Am J Cardiol. 2011;107(1):85–91.PubMedCentralPubMedCrossRef

19.

Alonso A, Krijthe BP, Aspelund T, Stepas KA, Pencina MJ, Moser CB, et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc. 2013;2(2):e000102. doi:10.1161/JAHA.112.000102.PubMedCentralPubMedCrossRef

20.

Knuiman MW, Hung J, Divitini ML, Davis TM, Beilby JP. Utility of the metabolic syndrome and its components in the prediction of incident cardiovascular disease: a prospective cohort study. Eur J Cardiovasc Prevent Rehabil. 2009;16(2):235–41. doi:10.1097/HJR.0b013e32832955fc.CrossRef

21.

Knuiman MW, James AL, Divitini ML, Bartholomew HC. Correlates of habitual snoring and witnessed apnoeas in Busselton, Western Australia. Aust N Z J Public Health. 2005;29(5):412–5.PubMedCrossRef

22.

Beilby J, Divitini ML, Knuiman MW, Rossi E, Hung J. Comparison of cystatin C and creatinine as predictors of cardiovascular events in a community-based elderly population. Clin Chem. 2010;56(5):799–804. doi:10.1373/clinchem.2009.135962.PubMedCrossRef

23.

Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome—an American Heart Association/National Heart, Lung, and Blood Institute scientific statement—executive summary. Circulation. 2005;112(17):E285–90.CrossRef

24.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment—insulin resistance and beta-cell function from fasting plasma-glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.PubMedCrossRef

25.

Chambless LE, Diao GQ. Estimation of time-dependent area under the ROC curve for long-term risk prediction. Stat Med. 2006;25(20):3474–86. doi:10.1002/Sim.2299.PubMedCrossRef

26.

Pencina MJ, D’Agostino RB, D’Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27(2):157–72. doi:10.1002/Sim.2929.PubMedCrossRef

27.

Marcus GM, Alonso A, Peralta CA, Lettre G, Vittinghoff E, Lubitz SA, et al. European ancestry as a risk factor for atrial fibrillation in African Americans. Circulation. 2010;122(20):2009–15.PubMedCentralPubMedCrossRef

28.

Mont L, Tamborero D, Elosua R, Molina I, Coll-Vinent B, Sitges M, et al. Physical activity, height, and left atrial size are independent risk factors for lone atrial fibrillation in middle-aged healthy individuals (vol 10, pg 15, 2008). Europace. 2008;10(3):386.

29.

Rosengren A, Hauptman PJ, Lappas G, Olsson L, Wilhelmsen L, Swedberg K. Big men and atrial fibrillation: effects of body size and weight gain on risk of atrial fibrillation in men. Eur Heart J. 2009;30(9):1113–20.PubMedCrossRef

30.

Conen D, Tedrow UB, Cook NR, Buring JE, Albert CM. Birth weight is a significant risk factor for incident atrial fibrillation. Circulation. 2010;122(8):764–70.PubMedCentralPubMedCrossRef

31.

Wanahita N, Messerli FH, Bangalore S, Gami AS, Somers VK, Steinberg JS. Atrial fibrillation and obesity—results of a meta-analysis. Am Heart J. 2008;155(2):310–5.PubMedCrossRef

32.

Everett BM, Conen D, Buring JE, Moorthy MV, Lee IM, Albert CM. Physical activity and the risk of incident atrial fibrillation in women. Circ-Cardiovasc Qual. 2011;4(3):321–7.CrossRef

33.

Healey JS, Connolly SJ. Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target. Am J Cardiol. 2003;91(10):9G–14G.PubMedCrossRef

34.

Shibata Y, Watanabe T, Osaka D, Abe S, Inoue S, Tokairin Y, et al. Impairment of pulmonary function is an independent risk factor for atrial fibrillation: the Takahata Study. Int J Med Sci. 2011;8(7):514–22.PubMedCentralPubMedCrossRef

35.

Buch P, Friberg J, Scharling H, Lange P, Prescott E. Reduced lung function and risk of atrial fibrillation in The Copenhagen City Heart Study. Eur Respir J. 2003;21(6):1012–6.PubMedCrossRef

36.

Rienstra M, Sun JX, Lubitz SA, Frankel DS, Vasan RS, Levy D, et al. Plasma resistin, adiponectin, and risk of incident atrial fibrillation: the Framingham Offspring Study. Am Heart J. 2012;163(1):119–24.PubMedCentralPubMedCrossRef

37.

Fontes JD, Lyass A, Massaro JM, Rienstra M, Dallmeier D, Schnabel RB, et al. Insulin resistance and atrial fibrillation (from the Framingham Heart Study). Am J Cardiol. 2012;109(1):87–90.PubMedCentralPubMedCrossRef

38.

Huxley RR, Alonso A, Lopez FL, Filion KB, Agarwal SK, Loehr LR, et al. Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the Atherosclerosis Risk in Communities study. Heart. 2012;98(2):133–8.PubMedCentralPubMedCrossRef

39.

Smith JG, Newton-Cheh C, Almgren P, Struck J, Morgenthaler NG, Bergmann A, et al. Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. J Am Coll Cardiol. 2010;56(21):1713–9.CrossRef

40.

Schnabel RB, Larson MG, Yamamoto JF, Sullivan LM, Pencina MJ, Meigs JB, et al. Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. Circulation. 2010;121(2):200–7.PubMedCentralPubMedCrossRef

41.

Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, et al. Inflammation as a risk factor for atrial fibrillation. Circulation. 2003;108(24):3006–10.PubMedCrossRef

42.

Gami AS, Pressman G, Caples SM, Kanagala R, Gard JJ, Davison DE, et al. Association of atrial fibrillation and obstructive sleep apnea. Circulation. 2004;110(4):364–7.PubMedCrossRef

43.

Needleman M, Calkins H. The role of obesity and sleep apnea in atrial fibrillation. Curr Opin Cardiol. 2011;26(1):40–5.PubMedCrossRef

44.

Selmer C, Olesen JB, Hansen ML, Lindhardsen J, Olsen AMS, Madsen JC, et al. The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. Brit Med J. 2012;345.

Titel: A cohort study examination of established and emerging risk factors for atrial fibrillation: the Busselton Health Study
verfasst von: Matthew Knuiman
Tom Briffa
Mark Divitini
Derek Chew
John Eikelboom
Brendan McQuillan
Joseph Hung
Publikationsdatum: 01.03.2014
Verlag: Springer Netherlands
Erschienen in: European Journal of Epidemiology / Ausgabe 3/2014
Print ISSN: 0393-2990
Elektronische ISSN: 1573-7284
DOI: https://doi.org/10.1007/s10654-013-9875-y

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2014

Frailty prevalence and 10-year survival in community-dwelling older adults: results from the ESTHER cohort study

Perinatal risk factors for Wilms tumor in a Swedish national cohort

Erratum to: The researcher and the consultant: a dialogue on null hypothesis significance testing

Is vitamin D deficiency a cause of increased morbidity and mortality at older age or simply an indicator of poor health?

Cognitive lifestyle jointly predicts longitudinal cognitive decline and mortality risk

All-cause mortality as an outcome in epidemiologic studies: proceed with caution